Table 3 Percentage of G2/M phase cells treated with tumor cells in different experimental groups.
From: Nanoemulsification of PTX and BEZ235 inhibits colon cancer growth
Percentage of G2/M phase cells (%) | |||||
|---|---|---|---|---|---|
Treatment | Cell | Treatment | Cell | ||
HT29 | HCT116 | HT29-DDP | HCT116-LOHP | ||
Control | 3.70 | 2.07 | Control | 3.43 | 2.50 |
NEs(1:1)-2.5 nM | 4.10 | 2.43 | NEs(1:1)-8 nM | 3.93 | 3.00 |
NEs(1:1)-10 nM | 4.83 | 3.20 | NEs(1:1)-16 nM | 4.57 | 4.10 |
NEs(1:2)-2.5 nM | 5.07 | 3.43 | NEs(1:2)-8 nM | 4.27 | 4.17 |
NEs(1:2)-10 nM | 6.27 | 4.83 | NEs(1:2)-16 nM | 5.43 | 5.63 |
NEs(1:4)-2.5 nM | 5.37 | 3.07 | NEs(1:4)-8 nM | 4.47 | 4.30 |
NEs(1:4)-10 nM | 6.27 | 4.50 | NEs(1:4)-16 nM | 5.50 | 5.30 |
NEs(1:8)-2.5 nM | 6.00 | 3.43 | NEs(1:8)-8 nM | 4.87 | 4.43 |
NEs(1:8)-10 nM | 8.60 | 5.33 | NEs(1:8)-16 nM | 5.97 | 6.03 |
NEs(1:10)-2.5 nM | 7.60 | 4.47 | NEs(1:10)-8 nM | 5.53 | 5.50 |
NEs(1:10)-10 nM | 10.87 | 7.07 | NEs(1:10)-16 nM | 6.53 | 7.00 |
